Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

  1. Öcal, Osman ORCID logo
  2. Schütte, Kerstin
  3. Kupčinskas, Juozas
  4. Morkunas, Egidijus
  5. Jurkeviciute, Gabija
  6. de Toni, Enrico N.
  7. Ben Khaled, Najib
  8. Berg, Thomas
  9. Malfertheiner, Peter
  10. Klümpen, Heinz Josef
  11. Sengel, Christian
  12. Basu, Bristi
  13. Valle, Juan W.
  14. Benckert, Julia
  15. Gasbarrini, Antonio
  16. Palmer, Daniel
  17. Seidensticker, Ricarda
  18. Wildgruber, Moritz
  19. Sangro, Bruno
  20. Pech, Maciej
  21. Ricke, Jens
  22. Seidensticker, Max ORCID logo

Download
s00432-021-03627-1.pdf 1,37MB
WeightNameValue
1000 Titel
  • Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
1000 Autor/in
  1. Öcal, Osman |
  2. Schütte, Kerstin |
  3. Kupčinskas, Juozas |
  4. Morkunas, Egidijus |
  5. Jurkeviciute, Gabija |
  6. de Toni, Enrico N. |
  7. Ben Khaled, Najib |
  8. Berg, Thomas |
  9. Malfertheiner, Peter |
  10. Klümpen, Heinz Josef |
  11. Sengel, Christian |
  12. Basu, Bristi |
  13. Valle, Juan W. |
  14. Benckert, Julia |
  15. Gasbarrini, Antonio |
  16. Palmer, Daniel |
  17. Seidensticker, Ricarda |
  18. Wildgruber, Moritz |
  19. Sangro, Bruno |
  20. Pech, Maciej |
  21. Ricke, Jens |
  22. Seidensticker, Max |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-14
1000 Erschienen in
1000 Quellenangabe
  • 148(2):475-485
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03627-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800931/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.!##!Methods!#!A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.!##!Results!#!Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9-8.9], p < 0.001) and IL-8 (HR, 2.4 [1.2-4.7], p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22-7.3], p = 0.017) and IL-8 (HR, 2.19 [1.02-4.7], p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%, p = 0.007; IL-8, 50.0% vs. 17.4%, p = 0.011).!##!Conclusion!#!IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.
1000 Sacherschließung
lokal Carcinoma, Hepatocellular/mortality [MeSH]
lokal Disease Progression [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Liver Neoplasms/mortality [MeSH]
lokal Turkey/epidemiology [MeSH]
lokal Aged [MeSH]
lokal Original Article – Clinical Oncology
lokal Sorafenib
lokal Liver Neoplasms/pathology [MeSH]
lokal Male [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Response
lokal Liver Neoplasms/diagnosis [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Hepatocellular carcinoma
lokal Carcinoma, Hepatocellular/diagnosis [MeSH]
lokal Carcinoma, Hepatocellular/pathology [MeSH]
lokal Survival Analysis [MeSH]
lokal Predictive Value of Tests [MeSH]
lokal Middle Aged [MeSH]
lokal Interleukin-8/blood [MeSH]
lokal Carcinoma, Hepatocellular/drug therapy [MeSH]
lokal Sorafenib/therapeutic use [MeSH]
lokal Europe/epidemiology [MeSH]
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Interleukin-6/blood [MeSH]
lokal Interleukin
lokal Liver Neoplasms/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-5234-1921|https://frl.publisso.de/adhoc/uri/U2Now7x0dGUsIEtlcnN0aW4=|https://frl.publisso.de/adhoc/uri/S3VwxI1pbnNrYXMsIEp1b3phcw==|https://frl.publisso.de/adhoc/uri/TW9ya3VuYXMsIEVnaWRpanVz|https://frl.publisso.de/adhoc/uri/SnVya2V2aWNpdXRlLCBHYWJpamE=|https://frl.publisso.de/adhoc/uri/ZGUgVG9uaSwgRW5yaWNvIE4u|https://frl.publisso.de/adhoc/uri/QmVuIEtoYWxlZCwgTmFqaWI=|https://frl.publisso.de/adhoc/uri/QmVyZywgVGhvbWFz|https://frl.publisso.de/adhoc/uri/TWFsZmVydGhlaW5lciwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/S2zDvG1wZW4sIEhlaW56IEpvc2Vm|https://frl.publisso.de/adhoc/uri/U2VuZ2VsLCBDaHJpc3RpYW4=|https://frl.publisso.de/adhoc/uri/QmFzdSwgQnJpc3Rp|https://frl.publisso.de/adhoc/uri/VmFsbGUsIEp1YW4gVy4=|https://frl.publisso.de/adhoc/uri/QmVuY2tlcnQsIEp1bGlh|https://frl.publisso.de/adhoc/uri/R2FzYmFycmluaSwgQW50b25pbw==|https://frl.publisso.de/adhoc/uri/UGFsbWVyLCBEYW5pZWw=|https://frl.publisso.de/adhoc/uri/U2VpZGVuc3RpY2tlciwgUmljYXJkYQ==|https://frl.publisso.de/adhoc/uri/V2lsZGdydWJlciwgTW9yaXR6|https://frl.publisso.de/adhoc/uri/U2FuZ3JvLCBCcnVubw==|https://frl.publisso.de/adhoc/uri/UGVjaCwgTWFjaWVq|https://frl.publisso.de/adhoc/uri/Umlja2UsIEplbnM=|https://orcid.org/0000-0002-2481-5410
1000 Hinweis
  • DeepGreen-ID: b8d2f4117d384587b7e832ce299244e9 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6449874.rdf
1000 Erstellt am 2023-05-09T10:26:57.669+0200
1000 Erstellt von 322
1000 beschreibt frl:6449874
1000 Zuletzt bearbeitet Sat Oct 21 02:10:13 CEST 2023
1000 Objekt bearb. Sat Oct 21 02:10:13 CEST 2023
1000 Vgl. frl:6449874
1000 Oai Id
  1. oai:frl.publisso.de:frl:6449874 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source